A Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SLV342 in Young Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Feb 2016
At a glance
- Drugs SLV 342 (Primary)
- Indications Atherosclerosis; Cardiovascular disorders; Lipid metabolism disorders
- Focus Adverse reactions
- Sponsors Abbott Laboratories
- 24 Aug 2011 Planned end date changed from 1 Oct 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov.
- 28 Sep 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 02 Feb 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.